Neurobiological Technologies (Neurobiological Technologies) Risk Assessment

View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Neurobiological Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of Neurobiological Technologies's Risk Assessment

For the Biotechnology subindustry, Neurobiological Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurobiological Technologies's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's Risk Assessment falls into.

Neurobiological Technologies (OTCPK:NTII) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Neurobiological Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurobiological Technologies (Neurobiological Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583

Website

http://www.ntii.com

Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Executives

Ariel Warszawski	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp	10 percent owner	426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp	10 percent owner	FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin	director
Abraham E Cohen	director	500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer	director	HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc	other: Direct Beneficial Owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines

From GuruFocus

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-12-2010

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 02-12-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 05-09-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009